Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension

• Main Authors: Amber Lundy, Nahla Lutfi, Cherylyn Beckey
• Format: Article
• Language: English
• Published: Dove Medical Press 2009-05-01
• Series: Vascular Health and Risk Management
• Online Access: http://www.dovepress.com/review-of-nifedipine-gits-in-the-treatment-of-high-risk-patients-with--a3113
• ISSN: 1176-6344; 1178-2048

Amber Lundy, Nahla Lutfi, Cherylyn BeckeyVeterans Affairs Medical Center, Pharmacy Service, West Palm Beach, FL, USAAbstract: Nifedipine is a dihydropyridine calcium-channel blocker (CCB) introduced approximately 30 years ago for the prophylaxis of angina symptoms, and then later utilized as an anti-hypertensive agent. In the 1990s, several meta-analyses and a case-control study were published which raised concern regarding increased mortality and increased risk for myocardial infarction with short-acting nifedipine. Further evaluation of these meta-analyses and case control study underscores some important limitations and the need to further elucidate the role of this class of medications in high-risk patients. Until 2000, there was a paucity of data on the long-term effects as well as the long-term outcomes of CCBs in the treatment of stable coronary disease or in patients with manifestations of the disease such as hypertension or angina. While it has been well established that nifedipine and other dihydropyridines lower blood pressure and improve symptoms of angina, several studies were designed to evaluate the effect of dihydropyridines on “hard” outcomes, specifically cardiovascular and cerebrovascular events. In this review, we describe the clinical studies evaluating the use of nifedipine when compared to placebo as well as other anti-hypertensive therapies in an attempt to identify the most appropriate place in therapy for this class of medications and to further clarify its utilization in high-risk patients. Keywords: nifedipine, dihydropyridine, ACTION, calcium-channel blocker, coronary heart disease, hypertension